FDA Accepts Supplement for INBRIJA (Levodopa) by Merz
The FDA has accepted a supplemental application for INBRIJA, an inhaled formulation of levodopa, submitted by Merz.
Asset / Drug
Drug and asset intelligence for INBRIJA with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.